Business
Completion of Technical Transfer & initial orders
Completion of Technical Transfer & initial orders.
About this update from Abingdon Health Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 2057H\n Abingdon Health PLC\n 05 April 2022\n \n \n \n \n Abingdon Health plc\n (\"Abingdon\" or \"the Company\")\n \n Completion of Technical Transfer to full-scale manufacture and initial orders for Vatic KnowNowTM test\n Tests manufactured by Abingdon now authorised for sale\n \n \n York, U.K. 5 April 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, announces it has successfully completed the technical transfer of the Vatic KnowNowᵀ test (Spike Test in USA) on behalf of its customer, leading diagnostics technology innovator Vatic Health Limited (\"Vatic\"), on schedule. This follows the conclusion of the scale-up and manufacture of three independent production-scale batches and Vatic has now approved the sale of tests manufactured by Abingdon. Abingdon has received initial purchase orders from Vatic for commercial sale, and manufacturing for these orders will now commence.\n \n The Vatic KnowNowᵀ test is an easy-to-use saliva COVID-19 antigen test, which is the only test that identifies the virus by mimicking the surface of a human cell. This means the test only identifies \"live\" or \"active\" copies of the virus which are capable of cell entry and thereby infecting a human cell. Other tests, such as PCR and lateral flow antigen tests, can pick up harmless viral fragments with the potential for users to test positive once they are no longer infectious. Furthermore, the unique detection mechanism of the KnowNowᵀ test has been purposefully designed to be more robust to mutation than traditional antigen tests, making it more future-proofed for ongoing COVID-19 testing. Vatic have previously announced that this test detects variants of the SARS-CoV-2 virus including the Omicron variant.\n \n The test is CE marked for professional use and has been submitted by Vatic to the US FDA for Emergency Use Approval (EUA).\n \n Alex Sheppard, CEO of Vatic Health Limited, commented:\n \"We are excited to have concluded the transfer of our product to manufacture with Abingdon and to commence sales of our product. Our proprietary technology allows ease of use via a saliva specimen and only detects active virus -enabling individuals to know their infectivity status.\"\n \n Dr Mona K. Omir...